Tumor necrosis factor biology in experimental and clinical arthritis

Current Opinion in Rheumatology

Volumn 15, Issue 4, 2003, Pages 380-386

  Sfikakis, Petros P ^a,c   Kollias, George ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOSYNTHESIS; CLINICAL PRACTICE; EXPERIMENTAL TEST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INFLAMMATION; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TISSUE INJURY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038772008     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200307000-00003     Document Type: Review

References (88)

1. Bathon JM, Martin RW, Fleischmann RM, et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593.
2. Lipsky PE, vander Heijde DM, St Clair EW, et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
3. Weinblatt ME, Keystone EC, Furst DE, et al.: Adalimumab, a fully human antitumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
4. Van den Bosch F, Kruithof E, Baeten D, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002, 46:755-765.
5. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346:1349-1356.
6. Braun J, Brandt J, Listing J, et al.: Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial. Lancet 2002, 359:1187-1193.
7. Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000, 356:385-390.
8. Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al.: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002, 47:506-512.
9. Bartolucci P, Ramanoelina J, Cohen P, et al.: Efficacy of the anti-TNF-a antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology 2002, 41:1126-1132.
10. Sfikakis PP, Theodossiades PG, Katsiari CG, et al.: Effect of infliximab in sight-threatening panuveitis in Behcet's disease. Lancet 2001, 358:295-296.
11. Sfikakis PP: Behcet's disease: a new target for anti-tumor necrosis factor treatment. Ann Rheum Dis 2002, 61 (suppl 2):ii51-ii53.
12. Furst DE, Breedveld FC, Kalden JR et al.: Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2002, 61 (suppl II):ii2-ii7.
13. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
14. Keffer J, Probert L, Cazlaris H, et al.: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-4031.
15. Wallach D, Varfolomeev EE, Malinin NL, et al.: Tumor necrosis factor receptor and fas signaling mechanisms. Annu Rev Immunol 1999, 17:331-367.
16. Kollias G, Douni E, Kassiotis G, et al.: On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999, 169:175-194.
17. McDermott MF; TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-Grand) 2001, 47:619-635. A comprehensive review of the molecular mechanics of TNF and its receptors at the physiological state and their deregulation in disease, including chronic inflammatory arthritis.
18. Kollias G, Kontoyiannis D, Douni E, et al.: The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized "anti-TNF" therapies. Curr Dir Autoimmun 2002, 5:30-50. A thorough discussion of experimental data on the dual role of TNF in the pathogenesis and progression of organ-specific and systemic autoimmunity. The heterogeneity of receptor usage by TNF in autoimmune suppression versus inflammatory tissue damage may provide clues for alternative anti-TNF therapeutic strategies.
19. Youn J, Kim HY: Park JH, et al.: Regulation on TNF-alpha-mediated hyperplasia through TNF receptors, TRAFs, and NF-kappa B in synoviocytes obtained from patients with rheumatoid arthritis. Immunol Lett 2002, 83:85-93.
20. Brennan FM, Hayes AL, Ciesielski CJ, et al.: Evidence that rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. Arthritis Rheum 2002, 46:31-41. This elegant study suggests that TNF production in chronic inflammatory rheumatoid tissues is a T cell-dependent process regulated differently from physiologic antigen-dependent TNF production.
21. McEvoy AN, Murphy EA, Ponnio T, et al.: Activation of nuclear orphan receptor NURR1 transcription by NF-kappa B and cyclic adenosine 5′-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol 2002, 168:2979-2987.
22. Sugiyama T, Ishii S, Yamamoto J, et al.: cDNA macroarray analysis of gene expression in synoviocytes stimulated with TNF alpha. FEBS Lett 2002, 517:121-128.
23. Feldmann M, Maini RN: Anti-TNF a therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001, 19:163-196. A comprehensive review of experimental and clinical studies which have implied that TNF is the key cytokine in the pathogenesis of RA.
24. Scott BB, Zaratin PF, Colombo A, et al.: Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002, 29:230-239.
25. Waldron-Lynch F, Adams C, Amos C, et al.: Tumor necrosis factor 5′ promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun 2001, 2:82-87.
26. Bridges SL Jr, Jenq G, Moran M, et al.: Single-nucleotide polymorphism in tumor necrosis factor receptor genes: definition of novel haplotypes and racial/ethnic differences. Arthritis Rheum 2002, 46:2045-2050.
27. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, et al.: Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-aipha, II-1beta and IL-1Ra genes. J Rheumatol 2002, 29:212-219.
28. Fabris M, Tolusso B, Di Poi E, et al.: Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002, 29:1847-1850.
29. Fabris M, Di PE, D'Elia A, et al.: Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis. J Rheumatol 2002, 29:29-33.
30. Mattey DL, Dawes PT, Fisher J, et al.: Nodular disease in rheumatoid arthritis: association with cigarette smoking and HLA-DRB1/TNF gene interaction. J Rheumatol 2002, 29:2313-2318.
31. Zeggini E, Thomson W, Alansari A, et al.: The British Paediatric Rheumatology Study Group. Tumour necrosis factor receptor II polymorphism and juvenile idiopathic arthritis. Rheumatology 2002, 41:462-465.
32. Ozen S, Alikasifoglu M, Bakkaloglu A, et al.: Tumour necrosis factor alpha G→a -238 and G→A -308 polymorphisms in juvenile idiopathic arthritis. Rheumatology 2002, 41:223-227.
33. Nishibu A, Oyama N, Nakamura K, et al.: Lack of association of TNF-238A and -308A in Japanese patients with psoriasis vulgaris, psoriatic arthritis and generalized pustular psoriasis. J Dermatol Sci 2002, 29:181-184.
34. Hohler T, Grossmann S, Stradmann-Bellinghausen B, et al.: Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis. Ann Rheum Dis 2002, 61:213-218.
35. Al-Heresh AM, Proctor J, Jones SM, et al.: Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxf) 2002, 41:525-530.
36. Rudwaleit M, Hohler T: Cytokine gene polymorphisms relevant for the spondyloarthropathies. Curr Opin Rheumatol 2001, 13:250-254.
37. Dayer JM, Krane SM: Anti-TNF-a therapy for ankylosing spondylitis: a specific or non-specific treatment? N Engl J Med 2002, 346:1399-1400.
38. Baeten D, Kruithof E, Van den Bosch F, et al.: Immunomodulatory effects of anti-TNF alpha therapy on synovium in spondyloarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001, 44:186-195.
39. Maini RN, Elliot MJ, Brennan FM, et al.: Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995, 144:195-223.
40. Papadaki HA, Kritikos HD, Vatatas V, et al.: Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 2002, 100:474-482. A prospective study suggesting that anemia of chronic disease in patients with RA is associated with TNF-mediated apoptosis of bone marrow erythroid precursor cells.
41. Papadaki HA, Kritikos HD, Gemetzi C, et al.: Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect. Blood 2002, 99:1610-1619.
42. Hurlimann D, Forster A, Noll G, et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
43. St Clair EW, Wagner CL, Fasanmade AA, et al.: The relationship of serum Infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:1451-1459.
44. Genovese MC, Bathon JM, Martin RW, et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
45. Lam J, Abu-Amer Y, Nelson CA, et al.: Tumor necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann Rheum Dis 2002, 61 (suppl II):ii82-ii83. A concise review of the authors own outstanding work on the pathogenesis of inflammatory ostolysis and the role of TNF.
46. Hofbauer LC, Heufelder AE: The role of osteoprotegerin and receptor activator of nuclear factor kB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001, 44:253-259.
47. Theill LE, Boyle WJ, Penninger JM: RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002, 20:795-823.
48. Abu-Amer Y, Erdmann J, Kollias G, et al.: Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoctastogenesis. J Biol Chem 2000, 275:27307-27310.
49. Romas E, Gillespie MT, Martin TJ: Involvement of receptor activator of NFkB ligand and tumor necrosis factor-a in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
50. Ziolkowska M, Kurowska M, Radzikowska A, et al.: High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002, 46:1744-1753. This the first evidence that in vivo neutralization of TNF in patients with RA is associated with normalization of serum levels of two key factors affecting bone metabolism, osteoprotogerin and RANKL. The results suggest a mechanism to explain the prevention of bone damage seen with this treatment.
51. Scallon BJ, Moore MA, Trih H, et al.: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
52. Scallon B, Cai A, Solowski N, et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426. This in vitro study shows the structure-related differences between etanercept and Infliximab in recognition and stability of their complexes with soluble and transmembrane TNF. If confirmed in vivo, these results may have important consequences for the use of anti-TNF agents in clinical practice.
53. van Deventer SJH: Transmembrane TNF-a, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease. Gastroenterology 2001, 121:1242-1245.
54. Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-607.
55. Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
56. Lee JH, Slifman NR, Gershon SK, et al.: Life-threatening histoplasmosis complicating immunotherapy with TNFa antagonists infliximab and etanercept. Arthritis Rheum 2002, 46:2565-2570.
57. Slifman NR, Gershon SK, Lee JH, et al.: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003, 48:319-324.
58. Tai TL, O'Rourke KP, McWeeney M, et al.: Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 2002, 41:951-952.
59. Cope A, Ettinger R, McDevitt H: The role of TNFa and related cytokines in the development and function of the autoreactive T cell repertoire. Res Immunol 1997, 148:307-312.
60. Theofilopoulos AN, Lawson BR: Tumor necrosis factor and other cytokines in murine lupus. Ann Rheum Dis 1999, 58(suppl 1 ):149-155.
61. Via CS, Shustov A, Rus V, et al.: In vivo neutralization on TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001, 167:6821-6826. An elegant study showing that induction of cytotoxic T cells in mice undergoing acute graft versus host disease is prevented by anti-TNF treatment. Because such T cells would normally suppress autoreactive B cells, these findings imply an additional protective activity of TNF.
62. Chades PJ, Smeenk RG, De Jong J, et al.: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNF alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000, 43:2383-2389.
63. Brown SL, Greene MH, Gershon SK, et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151-3158.
64. Shakoor N, Michalska M, Harris CA, et al.: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002, 359:579-580.
65. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1999, 53:457-465.
66. Mohan N, Edwards ET, Cupps TR, et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
67. Robinson WH, Genovese MC, Moreland LW: Demyelinating and neurologic events reported in association with TNF-a antagonism: by what mechanisms could TNF-a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001, 44:1977-1983.
68. Smith KJ, Skelton HG: Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001, 45:953-956.
69. Probert L, Plows D, Kontogeorgos G, et al.: The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol 1995, 6:1794-1797.
70. Douni E, Akasoglou K, Alexopoulou L, et al.: Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. J Inflamm 1996, 47:27-38.
71. Georgopoulos S, Plows D, Kollias G: Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 1996, 46:86-97.
72. Kontoyiannis D, Pasparakis M, Pizarro TT, et al.: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
73. Plows D, Kontogeorgos G, Kollias G: Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 1999, 162:1018-1023.
74. Sfikakis PP, Haralambous S, Kollias G: Effects of giucocorticoid and methotrexate administration on the tg 197 TNF-transgenic mouse model of chronic inflammatory polyarthritis. Arthritis Rheum 1998, 41 (suppl):S100.
75. Kaymakcalan Z, Beam C, Kamen R, et al.: Comparison of adalimumab, infliximab, and etanercept in the prevention of polyarthritis in a transgenic murine model of rheumatoid arthritis. Arthritis Rheum 2002, 46(suppl):S304.
76. Shealy DJ, Wooley PH, Emmell E, et al.: Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 2002, 4:R7.
77. Redlich K, Hayer S, Maier A, et al.: Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002, 46:785-792. Confirming that TNF-driven joint inflammation and joint destruction may occur uncoupled, this paper shows that osteoclast-targeted therapies reduce the number of bone-resorbing cells in the inflammatory tissues of TNF transgenic mice.
78. Mori L, Iselin S, De Libero G, et al.: Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 1996, 157:3178-3182.
79. Kuiper S, Joosten LA, Bendele AM, et al.: Different roles of TNFa and IL-1 in murine streptococcal cell wall arthritis. Cytokine 1998, 10:690-702.
80. Kagari T, Doi H, Shimozato T: The importance of IL-1 beta and TNF-alpha, and the non-involvement of IL-6, in the development of monoclonal antibody-induced arthritis. J Immunol 2002, 169:1456-1466.
81. Marinova-Mutafchieva L, Williams RO, Funa K, et al.: Inflammation is preceded by TNF-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002, 46:507-513.
82. Kim SH, Lechman ER, Kim S, et al.: Ex vivo gene delivery of IL-1 Ra and soluble TNF receptor confers a distal synergistic therapeutic effect in antigen-induced arthritis. Mol Ther 2002, 6:591-600.
83. Leung BP, Conacher M, Hunter D, et al.: A novel dendritic cell-induced model of erosive inflammatory arthritis: distinct roles for dendritic cells in T cell activation and induction of local inflammation. J Immunol 2002, 169:7071-7077.
84. Matsumo H, Yudoh K, Katayama R, et al.: The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology 2002, 41:329-337.
85. Ji H, Pettit A, Ohmura K, et al.: Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med 2002, 196:77-85. Elegant studies exploring the analogy between the K/BxN spontaneous mouse model of arthritis and human patients. TNF has a variable role in this model, reminiscent of that observed in patients with RA, which is not genetically programmed but rather relates to subtle environmental changes.
86. Redlich K, Hayer S, Ricci R, et al.: Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002, 110:1419-1427. An important paper showing that TNF transgenic mice lacking osteoclasts develop TNF-dependent arthritis but are fully protected against bone destruction.
87. Romas E, Sims NA, Hards DK, et al.: Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427. This study shows that short-term Fc-osteoprotegerin treatment depletes osteoclast numbers and effectively prevents joint destruction in the presence of inflammation in collagen-induced adhritis.
88. Kollias G, Kontoyiannis D: Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatment. Cytokine Growth Factor Rev 2002, 13:315-321.